EDUCATION
M.D. – Marmara University – Istanbul, Turkey

INTERESTS IN PATHOLOGY
Transfusion Medicine, Molecular Genetics

EXTRACURRICULAR ACTIVITIES
Yoga, Running

PUBLICATIONS

Costimulatory blockade-induced allograft survival requires Beclin1. Verghese DA, Yadav A, Bizargity P, Murphy B, Heeger PS, Schröppel B. Am J Transplant. 2014 Mar;14(3):545-53.

Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection. Bizargity P, Liu K, Wang L, Hancock WW, Visner GA. Transplantation. 2012 Jul 27;94(2):114-22.

Indoleamine 2,3-dioxygenase and metabolites protect murine lung allografts and impair the calcium mobilization of T cells. Iken K, Liu K, Liu H, Bizargity P, Wang L, Hancock WW, Visner GA.
Am J Respir Cell Mol Biol. 2012 Oct;47(4):405-16.

Transient modification within a pool of CD4 T cells in the maternal spleen. Bonney EA, Shepard MT, Bizargity P. Immunology. 2011 Nov;134(3):270-80.

The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis. Karadag-Saygi E, Akyuz G, Bizargity P, Ay P. Gynecol Endocrinol. 2011 Dec;27(12):1033-6.

Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Visner GA, Liu F, Bizargity P, Liu H, Liu K, Yang J, Wang L, Hancock WW. Transplantation. 2009 Aug 15;88(3):330-8.

Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression. Liu H, Liu L, Liu K, Bizargity P, Hancock WW, Visner GA. J Immunol. 2009 Jul 15;183(2):1022-31.

Pregnancy alters the proliferation and apoptosis of mouse splenic erythroid lineage cells and leukocytes. Norton MT, Fortner KA, Bizargity P, Bonney EA. Biol Reprod. 2009 Sep;81(3):457-64.

Resistance to lipopolysaccharide-induced preterm delivery mediated by regulatory T cell function in mice. Bizargity P, Del Rio R, Phillippe M, Teuscher C, Bonney EA.Biol Reprod. 2009 May;80(5):874-81.

Dendritic cells: a family portrait at mid-gestation. Bizargity P, Bonney EA. Immunology. 2009 Apr;126(4):565-78.

Imatinib does not inhibit neutrophil oxidative burst function in patients with chronic myelogenous leukemia. Bizargity P, Adigüzel C, Ozilhan G, Bayik M, Eksioglu-Demiralp E.
Clin Lab Haematol. 2005 Feb;27(1):79-80. “